Drew Moghanaki, Professor, Chief of Thoracic Oncology at the Department of Radiation Oncology and Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at David Geffen School of Medicine at UCLA, and Chief Medical Officer of Respirati, shared a post on X:
“The results of this study, led by Kara Marieruicci, are mind-boggling. While most clinical trials of systemic therapy for NSCLC, including many randomized phase II and III studies, allow for on-trial RT (off protocol), NONE (0%) of them actually collect any data on this additional anti-cancer therapy that could CERTAINTLY confound the results.”
Read Further: Day 1 Highlights from ASTRO 2025 by Drew Moghanaki.